prikaz prve stranice dokumenta Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium–Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the “Middle Child of HF”? Real-World Experience from a Single Clinical Centre
  Download
PDF 804.6 KB
Scientific paper - Original scientific paper
Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium–Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the “Middle Child of HF”? Real-World Experience from a Single Clinical Centre
Journal of Cardiovascular Development and Disease, 11 (2024), 6; 171. https://doi.org/10.3390/jcdd11060171
Viđak, Marin; Kursar, Jelena; Bodrožić Džakić Poljak, Tomislava; Letilović, Tomislav; Ćatić, Jasmina; Ivanović Mihajlović, Vanja; Zebić Mihić, Petra; Manola, Šime; Jurin, Ivana

Cite this document

Viđak, M., Kursar, J., Bodrožić Džakić Poljak, T., Letilović, T., Ćatić, J., Ivanović Mihajlović, V. ... Jurin, I. (2024). Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium–Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the “Middle Child of HF”? Real-World Experience from a Single Clinical Centre. Journal of Cardiovascular Development and Disease, 11. (6). doi: 10.3390/jcdd11060171

Viđak, Marin, et al. "Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium–Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the “Middle Child of HF”? Real-World Experience from a Single Clinical Centre." Journal of Cardiovascular Development and Disease, vol. 11, no. 6, 2024. https://doi.org/10.3390/jcdd11060171

Viđak, Marin, Jelena Kursar, Tomislava Bodrožić Džakić Poljak, Tomislav Letilović, Jasmina Ćatić, Vanja Ivanović Mihajlović, Petra Zebić Mihić, Šime Manola and Ivana Jurin. "Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium–Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the “Middle Child of HF”? Real-World Experience from a Single Clinical Centre." Journal of Cardiovascular Development and Disease 11, no. 6 (2024). https://doi.org/10.3390/jcdd11060171

Viđak, M., et al. (2024) 'Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium–Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the “Middle Child of HF”? Real-World Experience from a Single Clinical Centre', Journal of Cardiovascular Development and Disease, 11(6). doi: 10.3390/jcdd11060171

Viđak M, Kursar J, Bodrožić Džakić Poljak T, Letilović T, Ćatić J, Ivanović Mihajlović V, and sur.. Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium–Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the “Middle Child of HF”? Real-World Experience from a Single Clinical Centre. Journal of Cardiovascular Development and Disease [Internet]. 2024 May 31 [cited 2025 February 21];11(6). doi: 10.3390/jcdd11060171

M. Viđak, et al., "Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium–Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the “Middle Child of HF”? Real-World Experience from a Single Clinical Centre", Journal of Cardiovascular Development and Disease, vol. 11, no. 6, May 2024. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:577388. [Accessed: 21 February 2025]

Please login to the repository to save this object to your list.
Metadata
Title (english)Heart Failure with Mid-Range or Mildly Reduced Ejection Fraction in the Era of Sodium–Glucose Co-Transporter 2 Inhibitors: Do We Now Provide Better Care for the “Middle Child of HF”? Real-World Experience from a Single Clinical Centre
AuthorMarin Viđak
AuthorJelena Kursar
AuthorTomislava Bodrožić Džakić Poljak
AuthorTomislav Letilović
AuthorJasmina Ćatić
AuthorVanja Ivanović Mihajlović
AuthorPetra Zebić Mihić
AuthorŠime Manola
AuthorIvana Jurin
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Internal Medicine)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract (english)
Heart failure (HF) with mid-range or mildly reduced ejection fraction (HFmrEF) is a separate clinical entity in the HF spectrum, with a left ventricular ejection fraction ranging from 40 to 49%. While sodium glucose co-transporter 2 inhibitors have become the cornerstone therapy for the entire HF spectrum, there are a few clinical trials of HFmrEF. This prospective observational study was conducted at Dubrava University Hospital, Zagreb, Croatia, from May 2021 to October 2023. We recruited 137 participants diagnosed with HFmrEF at admission. The majority were male, with a median age of 72 and overweight. A total of 110 participants were followed for 6 months and LVEF remained the same in the majority of patients (n = 62, 56.4%), improved in 32 patients (29.1%), and decreased in 3 patients (2.73%). A total of 64 participants were followed for 12 months: 39 remained the same (60.94%) and 25 improved. There were 13 deaths in (9.5%). While the empagliflozin group had a lower BMI at 6-month- and lower HbA1c at 12-month follow-up, there were no differences in death, HF hospitalizations, ER visits, or urinary tract infections in between groups. Despite recent and daily advances in the treatment of all HF phenotypes, HFmrEF still represents a challenge in everyday clinical practice.
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Cardiovascular Development and Disease
Numberingvol. 11, no. 6, 171
e-ISSN2308-3425
DOIhttps://doi.org/10.3390/jcdd11060171
URN:NBNurn:nbn:hr:105:577388
Publication2024-05-31
Document URLhttps://www.mdpi.com/2308-3425/11/6/171
Type of resourceText
Access conditionsOpen access
Terms of useLicence Attribution 4.0 International (CC BY 4.0) icon
Created on2025-01-20 11:45:29